News | May 01, 2023
IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The appointment is effective from May 01, 2023 for five years
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
